Restricted accessResearch articleFirst published online 2017-7
Preventing the Progression of Intestinal Failure–Associated Liver Disease in Infants Using a Composite Lipid Emulsion: A Pilot Randomized Controlled Trial of SMOFlipid
Background: To examine whether SMOFlipid prevents progression of intestinal failure–associated liver disease (IFALD) in parenteral nutrition (PN)–dependent infants with early IFALD (conjugated bilirubin 17–50 µmol/L, 1-3 mg/dL). Study Design: Pilot multicenter blinded randomized controlled trial comparing SMOFlipid with Intralipid. Patients received the trial lipid for up to 12 weeks, unless they achieved full enteral tolerance sooner. The primary clinical outcome was the serum conjugated bilirubin. Results: Twenty-four infants (mean age, 6 weeks) participated in the trial (13 Intralipid and 11 SMOFlipid). At the time of trial enrollment, patients in both groups were receiving 90% of their calories by PN. Mean duration on trial was 8 weeks and did not differ according to treatment (P = .99). At trial conclusion, patients who received SMOFlipid had a lower conjugated bilirubin than those who received Intralipid (mean difference, –59 µmol/L; P = .03). Patients receiving SMOFlipid were also more likely to have a decrease in serum conjugated bilirubin to 0 µmol/L than those in the Intralipid group over the entire observation period (hazard ratio, 10.6; 95%; P = .03). The time to achievement of full enteral tolerance did not differ statistically (hazard ratio, 1.3; P = .59) between the groups. There was no significant difference in safety outcomes between the groups. Conclusions: Compared with Intralipid, SMOFlipid reduces the risk of progressive IFALD in children with intestinal failure. This trial was registered at clinicaltrials.gov as NCT00793195.
WalesPWDe SilvaNKimJLecceLToTMooreAM.Population-based estimates of incidence and mortality rates. J Pediatr Surg. 2004;39:690-695.
2.
WalesPWde SilvaNKimJHLecceLSandhuAMooreAM.Neonatal short bowel syndrome: a cohort study. J Pediatr Surg. 2005;40:755-762.
3.
AndorskyDJLundDPLilleheiCWNutritional and other postoperative management of neonates with short bowel syndrome correlates with clinical outcomes. J Pediatr. 2001;139(1):27-33.
4.
WarnerBWZieglerMM.Management of the short bowel syndrome in the pediatric population. Pediatr Clin North Am. 1993;40(6):1335-1350.
5.
KaufmanSS.Prevention of parenteral nutrition–associated liver disease in children. Pediatr Transplant. 2002;6(1):37-42.
6.
GouletOJolyFCorriolOColomb-JungV.Some new insights in intestinal failure–associated liver disease. Current Opin Organ Transplant. 2009;14(3):256-261.
7.
DiamondIRSterescuAPencharzPBWalesPW.The rationale for the use of parenteral omega-3 lipids in children with short bowel syndrome and liver disease. Pediatr Surg Int. 2008;24:773-778.
CavicchiMBeauPCrennPDegottCMessingB.Prevalence of liver disease and contributing factors in patients receiving home parenteral nutrition for permanent intestinal failure. Ann Intern Med. 2000;132(7):525-532.
10.
Van AerdeJEDuerksenDRGramlichLIntravenous fish oil emulsion attenuates total parenteral nutrition–induced cholestasis in newborn piglets. Pediatr Res. 1999;45(2):202-208.
11.
LlopJMVirgiliNMoreno-VillaresJMPhytosterolemia in parenteral nutrition patients: implications for liver disease development. Nutrition. 2008;24(11-12):1145-1152.
12.
ClaytonPTBowronAMillsKAMassoudACasteelsMMillaPJ.Phytosterolemia in children with parenteral nutrition–associated cholestatic liver disease. Gastroenterology. 1993;105(6):1806-1813.
13.
El KasmiKCAndersonALDevereauxMWPhytosterols promote liver injury and Kupffer cell activation in parenteral nutrition–associated liver disease. Sci Transl Med. 2013;5(206):1-15.
14.
HellerAKochTSchmeckJvan AckernK.Lipid mediators in inflammatory disorders. Drugs. 1998;55(4):487-496.
15.
BroughtonKSWadeJW.Total fat and (n-3):(n-6) fat ratios influence eicosanoid production in mice. J Nutr. 2002;132(1):88-94.
16.
GrimmHTibellANorrlindBImmunoregulation by parenteral lipids: impact of the n-3 to n-6 fatty acid ratio. JPEN J Parenter Enteral Nutr. 1994;18(5):417-421.
17.
AntebiHMansoorOFerrierCLiver function and plasma antioxidant status in intensive care unit patients requiring total parenteral nutrition: comparison of 2 fat emulsions. JPEN J Parenter Enteral Nutr. 2004;28(3):142-148.
18.
GrimmHMertesNGoetersCImproved fatty acid and leukotriene pattern with a novel lipid emulsion in surgical patients. Eur J Nutr. 2006;45(1):55-60.
19.
NgKStollBChackoSVitamin E in new-generated lipid emulsions protects against parenteral nutrition–associated liver disease in parenteral nutrition–fed preterm pigs [published online January16, 2015]. JPEN J Parenter Enteral Nutr.
20.
ParkHWLeeNMKimJHKimKSKimSN.Parenteral fish oil–containing lipid emulsions may reverse parenteral nutrition–associated cholestasis in neonates: a systematic review and meta-analysis. J Nutr. 2015;145:277-283.
21.
MuhammedRBremnerRProtheroeSJohnsonTHoldenCMurphyMS.Resolution of parenteral nutrition–associated jaundice on changing from a soybean oil emulsion to a complex mixed-lipid emulsion. J Pediatr Gastroenterol Nutr. 2012;54(6):797-802.
22.
DiamondIRSterescuAPencharzPBKimJHWalesPW.Changing the paradigm: Omegaven for the treatment of liver failure in pediatric short bowel syndrome. J Pediatr Gastroenterol Nutr. 2009;48(2):209-215.
DiamondIRPencharzPBWalesPW.What is the current role for parenteral lipid emulsions containing omega-3 fatty acids in infants with short bowel syndrome?Minerva Pediatr. 2009;61:263-272.
27.
JosephsonJTurnerJMFieldCJParenteral soy oil and fish oil emulsions: impact of dose restriction on bile flow and brain size of parenteral nutrition–fed neonatal piglets. JPEN J Parenter Enteral Nutr. 2015;39(6):677-687.
28.
RollinsMDWardRMJacksonWDEffect of decreased parenteral soybean lipid emulsion on hepatic function in infants at risk for parenteral nutrition–associated liver disease: a pilot study. J Pediatr Surg. 2013;48(6):1348-1356.
29.
NehraDFallonEMCarlsonSJProvision of a soy-based intravenous lipid emulsion at 1 g/kg/d does not prevent cholestasis in neonates. JPEN J Parenter Enteral Nutr. 2013;37(4):498-505.
30.
CoberMPKilluGBrattainAWelchKBKunisakiSMTeitelbaumDH.Intravenous fat emulsions reduction for patients with parenteral nutrition–associated liver disease. J Pediatr. 2012;160(3):421-427.
31.
RollinsMDScaifeERJacksonWDMeyersRLMulroyCWBookLS.Elimination of soybean lipid emulsion in parenteral nutrition and supplementation with enteral fish oil improve cholestasis in infants with short bowel syndrome. Nutr Clin Pract. 2010;25(2):199-204.
32.
ShinJINamgungRParkMSLeeC.Could lipid infusion be a risk for parenteral nutrition–associated cholestasis in low birth weight neonates?Eur J Pediatr. 2008;167(2):197-202.
33.
ColombVJobert-GiraudALacailleFGouletOFournetJCRicourC.Role of lipid emulsions in cholestasis associated with long-term parenteral nutrition in children. JPEN J Parenter Enteral Nutr. 2000;24(6):345-350.
34.
LamHSTamYHPoonTCWA double-blind randomized controlled trial of fish oil–based versus soy-based lipid preparations in the treatment of infants with parenteral nutrition–associated cholestasis. Neonatology. 2014;105:290-296.
35.
CalkinsKLHavranekTKelley-QuonLLow-dose parenteral soybean oil for the prevention of parenteral nutrition–associated liver disease in neonates with gastrointestinal disorders: a multicenter randomized controlled pilot study [published online May29, 2015]. JPEN J Parenter Enteral Nutr.
36.
GuraKMDugganCPCollierSBReversal of parenteral nutrition–associated liver disease in two infants with short bowel syndrome using parenteral fish oil: implications for future management. Pediatrics. 2006;118(1):e197-e201.
37.
GouletOAntebiHWolfCA new intravenous fat emulsion containing soybean oil, medium-chain triglycerides, olive oil, and fish oil: a single-center, double-blind randomized study on efficacy and safety in pediatric patients receiving home parenteral nutrition. JPEN J Parenter Enteral Nutr. 2010;34(5):485-495.
38.
SkouroliakouMKonstantinouDKoutriKA double-blind, randomized clinical trial of the effect of omega-3 fatty acids on the oxidative stress of preterm neonates fed through parenteral nutrition. Eur J Clin Nutr. 2010;64(9):940-947.
39.
TomsitsEPatakiMTolgyesiAFeketeGRischakKSzollarL.Safety and efficacy of a lipid emulsion containing a mixture of soybean oil, medium-chain triglycerides, olive oil, and fish oil: a randomised, double-blind clinical trial in premature infants requiring parenteral nutrition. J Pediatr Gastroenterol Nutr. 2010;51(4):514-521.
40.
RayyanMDevliegerHJochumFAllegaertK.Short-term use of parenteral nutrition with a lipid emulsion containing a mixture of soybean oil, olive oil, medium-chain triglycerides, and fish oil: a randomized double-blind study in preterm infants. JPEN J Parenter Enteral Nutr. 2012;36(1)(suppl):81S-94S.
41.
MossRLHenryMCDimmittRARangelSGeraghtyNSkarsgardED. The role of prospective randomized clinical trials in pediatric surgery: state of the art?J Pediatr Surg. 2001;36:1182-1186.
42.
HadawayLC.Best-practice interventions: keeping central line infection at bay. Nursing. 2006;36:58-64.
43.
BealeEFNelsonRMBucciarelliRLDonnellyWHEitzmanDV.Intrahepatic cholestasis associated with parenteral nutrition in premature infants. Pediatrics. 1979;64:342-347.
44.
ChristensenRDHenryEWiedmeierSEBurnettJLambertDK.Identifying patients, on the first day of life, at high-risk of developing parenteral nutrition–associated liver disease. J Perinatol. 2007;27:284-290.
45.
DuroDKalishLAJohnstonPRisk factors for intestinal failure in infants with necrotizing enterocolitis: a Glaser Ped Res Network Study. J Pediatr. 2010;157:203-208.e1.
46.
FischlerLMeredithDOReinhartWH.Influence of a parenteral fish-oil preparation (Omegaven) on erythrocyte morphology and blood viscosity in vitro. Clin Hemorheol Microcirc. 2003;28:79-88.
47.
WalesPWAllenNWorthingtonPGeorgeDCompherC; the American Society for Parenteral and Enteral Nutrition, Teitelbaum D. A.S.P.E.N. Clinical Guidelines: support of pediatric patients with intestinal failure at risk of parenteral nutrition–associated liver disease. JPEN J Parenter Enteral Nutr. 2014;38(5):538-557.
48.
SeidaJCMagerDRHartlingLVandermeerBTurnerJM.Parenteral ω-3 fatty acid lipid emulsions for children with intestinal failure and other conditions: a systematic review. JPEN J Parenter Enteral Nutr. 2013;37(1):44-55.
49.
VanekVWSeidnerDLAllenP; Novel Nutrient Task Force, Intravenous Fat Emulsions Workgroup; American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.) Board of Directors. A.S.P.E.N. position paper: clinical role for alternative intravenous fat emulsions. Nutr Clin Pract. 2012;27(2):150-192.
Gastroenterology Regulatory Endpoints and the Advancement of Therapeutics (GREAT): Parenteral Nutrition-Induced Liver Disease (PNALD) workshop. Maryland, September24, 2012. http://www.regulations.gov/#!documentDetail;D=FDA-2012-N-0001-0093. Accessed April 20, 2013.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
